Company / R&D per Share
NOVAVAX INC R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.13
FY2025
5-year range
$2.13 / $35.72
FY2021-FY2025
Trend
-23.9%
vs FY2024
Sector context
#96 of 208
Health Care
What the data says
At $2.13, NOVAVAX INC's r&d per share ranks #96 of 208 in the Health Care sector. R&D per Share has declined for 4 consecutive years, from $35.72 in FY2021 to $2.13 in FY2025.
Based on SEC 10-K filings.
2.13 in FY2025 with a 5-year CAGR of -37.9%.
Declined from $8.57 to $2.13 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -39.9%
- 5-Year CAGR
- -37.9%
- 10-Year CAGR
- -
Sector benchmark
#96 of 208 in Health CareTop 46% of 208This company $2.13 Sector average $12.19
▼
-82.5% below sector average
Key checks
Key Insights
- NOVAVAX INC's r&d per share has declined for 4 consecutive years.
- In FY2025, r&d per share decreased 23.9% year-over-year.
- Ranks #96 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.13 | -23.9% |
| FY2024 | $2.80 | -67.3% |
| FY2023 | $8.57 | -13.0% |
| FY2022 | $9.85 | -72.4% |
| FY2021 | $35.72 | +54.7% |
| FY2020 | $23.09 | +163.5% |
| FY2019 | $8.76 | +1090.3% |
| FY2018 | $0.74 | +22.8% |
| FY2017 | $0.60 | +71.4% |
| FY2016 | $0.35 | +42.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026